SCM
AGIO icon

Suvretta Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Suvretta Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-399,451
Closed -$8.9M – 102
2023
Q4 		$8.9M Sell
399,451
-54,549
-12% -$1.22M 0.4% 46
2023
Q3 		$11.2M Hold
454,000
– – 0.61% 43
2023
Q2 		$12.9M Hold
454,000
– – 0.69% 47
2023
Q1 		$10.4M Sell
454,000
-231,772
-34% -$6.16M 0.44% 51
2022
Q4 		$19.3M Sell
685,772
-273,442
-29% -$7.71M 0.81% 41
2022
Q3 		$27.1M Sell
959,214
-1,362,586
-59% -$36.5M 1.13% 37
2022
Q2 		$51.5M Buy
2,321,800
+1,144,426
+97% +$25.8M 1.96% 19
2022
Q1 		$34.3M Hold
1,177,374
– – 1.05% 35
2021
Q4 		$38.7M Sell
1,177,374
-134,374
-10% -$5.41M 0.75% 37
2021
Q3 		$60.5M Buy
1,311,748
+324,292
+33% +$15.7M 1.02% 31
2021
Q2 		$54.4M Sell
987,456
-93,891
-9% -$5.25M 0.81% 37
2021
Q1 		$55.8M Buy
1,081,347
+891,047
+468% +$44.1M 0.83% 38
2020
Q4 		$8.25M Buy
+190,300
New +$7.52M 0.12% 66

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Suvretta Capital Management's AGIO Position: Q1 2024 in Review

Suvretta Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2024, closing a stake of 399,451 shares — an estimated $8.9M sold.

Suvretta Capital Management first reported a position in AGIO in Q4 2020 and held it in 13 quarters. The position peaked at $60.5M in Q3 2021. 186 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.

  • Suvretta Capital Management reported no remaining Agios Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 399,451 Agios Pharmaceuticals shares in Q1 2024, an estimated $8.9M.
  • Suvretta Capital Management first reported a position in Agios Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Suvretta Capital Management's Agios Pharmaceuticals position peaked at $60.5M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.

Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.